Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandria Matic

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Immunotherapy|April 25, 2025
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospectsAlexandria Matic, Vera Bril
Expert Opinion on Biological Therapy|December 15, 2023
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravisAlexandria Matic, Nouf Alfaidi, Vera Bril
CNS Drugs|May 9, 2024
FcRn Inhibitor Therapies in Neurologic DiseasesNouf Alfaidi, Salama Karmastaji, Alexandria Matic, et al.
International Review of Neurobiology|October 16, 2025
Clinical outcome measuresAlexandria Matic, Yvonne Campman, Martijn Rudolf Tannemaat, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Immunotherapy|April 25, 2025
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospectsAlexandria Matic, Vera Bril
Expert Opinion on Biological Therapy|December 15, 2023
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravisAlexandria Matic, Nouf Alfaidi, Vera Bril
CNS Drugs|May 9, 2024
FcRn Inhibitor Therapies in Neurologic DiseasesNouf Alfaidi, Salama Karmastaji, Alexandria Matic, et al.
International Review of Neurobiology|October 16, 2025
Clinical outcome measuresAlexandria Matic, Yvonne Campman, Martijn Rudolf Tannemaat, et al.
Pageof 1